Clinical Trial Update: An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II) [Phase 4]

View source ↗

Summary

Phase 4 open-label study evaluating every-other-week dosing of epoetin alfa (PROCRIT) to maintain quality of life and target hemoglobin in anemic HIV-infected p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• HIV Infection

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Ortho Biotech Products, L.P. | Conditions: Anemia, HIV Infections | Phase 4 | Status: COMPLETED